CD253 Recombinant Protein from ProteoGenix; catalogue PX-P4111; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Recombinant human CD253 is a 19.6 kDa protein consisting of 168 amino acids, corresponding to the TNF homologous region of the human TRAIL / ApoL2 extracellular domain. TNF-induced ligand apoptosis (TRAIL) is expressed in many tissues including spleen, lung, and prostate and can induce apoptosis depending on specific tumors. Apoptosis begins with the combination of two death receptors DR4 and DR5, which trigger cell death through the Caspian cascade. However, there are two types of ornamental receptors DcR1 and DcR2 that competitively bind to CD253, but do not induce apoptosis. The possible use of TRAIL as a therapeutic anticancer agent has been confirmed in numerous studies, which have shown that about two thirds of the tumor cell lines tested have tumoricidal activity. Recombinant human CD253 is a rabbit immunogen used to produce anti-human CD253.
ProteoGenix catalogue number PX-P4111. For research use only.
Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Purity: >90% by SDS-PAGE; Molecular weight: 33.78kDa; Tag: C-terminal His Tag; Fragment: Met1~Gly281; Buffer: PBS pH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
